Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst
News release
by
Tiziana Life Sciences PLC
London, UK
|
May 05, 2023 10:49 AM Eastern Daylight Time
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage biopharmaceutical company Tiziana Life Sciences Ltd (NASDAQ:TLSA). Tiziana has disclosed plans to file INDs (Investigational New Drug applications) aiming to expand the clinical indications of its lead product, intranasal foralumab, into mild-to-moderate Alzheimer’s Disease (AD) and long COVID-19.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
